0000950103-14-004566.txt : 20140701 0000950103-14-004566.hdr.sgml : 20140701 20140701135145 ACCESSION NUMBER: 0000950103-14-004566 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20140701 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140701 DATE AS OF CHANGE: 20140701 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 14951737 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: R924 8EP BUSINESS PHONE: 441256894000 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: R924 8EP FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp47588_8k.htm FORM 8-K
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 1, 2014

Shire plc
_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands
_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486
(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin
24, Republic of Ireland
_________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700


_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))
 
 
 
 
 
Item 8.01.   Other Events

Shire plc have issued the public disclosures attached hereto as Exhibits 99.1 through 99.8 which are incorporated by reference herein.


Item 9.01.   Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibits are filed herewith:

99.1
Public disclosure
99.2
Public disclosure
99.3
Public disclosure
99.4
Public disclosure
99.5
Public disclosure
99.6
Public disclosure
99.7
Public disclosure
99.8
Public disclosure
 
 
 
 

 
SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
SHIRE PLC
   
   
 
By:
 /s/ T May
    Name: Tatjana May
    Title: General Counsel
 
Dated: July 1, 2014
 
 
 
 
 
 
EXHIBIT INDEX
 
Number
Description
   
99.1
Public disclosure
   
99.2
Public disclosure
   
99.3
Public disclosure
   
99.4
Public disclosure
   
99.5
Public disclosure
   
99.6
Public disclosure
   
99.7
Public disclosure
   
99.8
Public disclosure
 
 
EX-99.1 2 dp47588_ex9901.htm EXHIBIT 99.1
Exhibit 99.1
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a)  Identity of the party to the offer or person acting in concert making the disclosure:
Dr Steven Gillis
(b)  Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
  
(c)  Name of offeror/offeree in relation to whose relevant securities this form relates:
 Use a separate form for each offeror/offeree
Shire plc
(d)  Status of person making the disclosure:
 e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e)  Date dealing undertaken:
30 June 2014
(f)   Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing
 
Class of relevant security:
1 ADS = 3 x 5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
402 ADS = 1,206 ordinary shares
 
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
402 ADS = 1,206 ordinary shares
 
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
1 ADS = 3 x 5p ordinary shares
Purchase
 
36 ADS = 108 ordinary shares
USD 235.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
 
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.
 
 
 
 
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 EX-99.2 3 dp47588_ex9902.htm EXHIBIT 99.2
Exhibit 99.2
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a) Identity of the party to the offer or person acting in concert making the disclosure:
David Stout
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
  
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Shire plc
(d) Status of person making the disclosure:
e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e) Date dealing undertaken:
30 June 2014
(f)  Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing
 
Class of relevant security:
1 ADS = 3 x 5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
403 ADS = 1,209 ordinary shares
 
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
403 ADS = 1,209 ordinary shares
 
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
1 ADS = 3 x 5p ordinary shares
Purchase
 
37 ADS = 111 ordinary shares
USD 235.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.
 
 
 
 
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 EX-99.3 4 dp47588_ex9903.htm EXHIBIT 99.3
Exhibit 99.3
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a) Identity of the party to the offer or person acting in concert making the disclosure:
Susan Kilsby
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
  
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Shire plc
(d) Status of person making the disclosure:
e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e) Date dealing undertaken:
30 June 2014
(f)  Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing
 
Class of relevant security:
1 ADS = 3 x 5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
441 ADS = 1,323 ordinary shares
 
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
441 ADS = 1,323 ordinary shares
 
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
1 ADS = 3 x 5p ordinary shares
Purchase
 
91 ADS = 273 ordinary shares
USD 235.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
 
 
 
 
4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

 
For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 EX-99.4 5 dp47588_ex9904.htm EXHIBIT 99.4
Exhibit 99.4
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a)  Identity of the party to the offer or person acting in concert making the disclosure:
Anne Minto
(b)  Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
  
(c)  Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Shire plc
(d)  Status of person making the disclosure:
 e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e)  Date dealing undertaken:
30 June 2014
(f)   Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing
 
Class of relevant security:
5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
3,511 ordinary shares
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
3,511 ordinary shares
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
5p ordinary shares
Purchase
 
120 ordinary shares
GBP 46.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
 
 
 
 
4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii)  the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

 
For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 
 
EX-99.5 6 dp47588_ex9905.htm EXHIBIT 99.5
Exhibit 99.5
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a) Identity of the party to the offer or person acting in concert making the disclosure:
David Kappler
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
  
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Shire plc
(d) Status of person making the disclosure:
e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e) Date dealing undertaken:
30 June 2014
(f)  Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing
 
Class of relevant security:
5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
11,322 ordinary shares
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
11,322 ordinary shares
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
5p ordinary shares
Purchase
 
120 ordinary shares
GBP 46.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
 
 
 
 
4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii)  the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.


 
For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 EX-99.6 7 dp47588_ex9906.htm EXHIBIT 99.6
Exhibit 99.6
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a)Identity of the party to the offer or person acting in concert making the disclosure:
William Burns
(b)  Owner or controller of interests and short positions disclosed, if different from 1(a):
 The naming of nominee or vehicle companies is insufficient
  
(c)  Name of offeror/offeree in relation to whose relevant securities this form relates:
 Use a separate form for each offeror/offeree
Shire plc
(d)  Status of person making the disclosure:
 e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e)  Date dealing undertaken:
30 June 2014
(f)   Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing
 
 
Class of relevant security:
5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
1,268 ordinary shares
 
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
1,268 ordinary shares
 
<0.01%
 
Nil
0
 

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
5p ordinary shares
Purchase
 
115 ordinary shares
GBP 46.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
 
 
 
 
4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

 
For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 
 
EX-99.7 8 dp47588_ex9907.htm EXHIBIT 99.7
Exhibit 99.7
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a)  Identity of the party to the offer or person acting in concert making the disclosure:
Dominic Blakemore
(b)  Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
  
(c)  Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Shire plc
(d)  Status of person making the disclosure:
 e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e)  Date dealing undertaken:
30 June 2014
(f)   Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 
Class of relevant security:
5p ordinary shares
 
Interests
Short positions
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
248 ordinary shares
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
248 ordinary shares
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
5p ordinary shares
Purchase
 
101 ordinary shares
GBP 46.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
 
 
 
 
4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
 
 
For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 
 
EX-99.8 9 dp47588_ex9908.htm EXHIBIT 99.8
Exhibit 99.8
 
Press Release
www.shire.com
  
 
FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1.           KEY INFORMATION

(a)  Identity of the party to the offer or person acting in concert making the disclosure:
Dr David Ginsburg
(b)  Owner or controller of interests and short positions disclosed, if different from 1(a):
 The naming of nominee or vehicle companies is insufficient
  
(c)  Name of offeror/offeree in relation to whose relevant securities this form relates:
 Use a separate form for each offeror/offeree
Shire plc
(d)  Status of person making the disclosure:
 e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)
Director of Offeree
(e)  Date dealing undertaken:
30 June 2014
(f)   Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?
NO

2.           POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

 
Class of relevant security:
1 ADS = 3 x 5p ordinary shares
 
Interests
Short positions
  
 
Number
%
Number
%
(1)  Relevant securities owned and/or controlled:
385 ADS = 1,155 ordinary shares
 
<0.01%
 
Nil
0
(2)  Derivatives (other than options):
Nil
0
Nil
0
(3)  Options and agreements to purchase/sell:
Nil
0
Nil
0
 
TOTAL:
385 ADS = 1,155 ordinary shares
 
<0.01%
 
Nil
0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)
Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
None
Details, including nature of the rights concerned and relevant percentages:
None
 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.           DEALINGS BY THE PERSON MAKING THE DISCLOSURE

(a)           Purchases and sales

Class of relevant security
Purchase/sale
 
Number of securities
Price per unit
1 ADS = 3 x 5p ordinary shares
Purchase
 
34 ADS = 102 ordinary shares
USD 235.50

(b)           Derivatives transactions (other than options)

Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
n/a
n/a
 
n/a
n/a
n/a

(c)           Options transactions in respect of existing securities

(i)           Writing, selling, purchasing or varying

Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

(ii)           Exercising

Class of relevant security
Product description
e.g. call option
Number of securities
Exercise price per unit
n/a
n/a
n/a
n/a

(d)           Other dealings (including subscribing for new securities)

Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
n/a
n/a
n/a
n/a

The currency of all prices and other monetary amounts should be stated.
 
 
 
 
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4.           OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(b)           Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None
 

(c)           Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)
NO
Supplemental Form 8 (SBL)
NO


Date of disclosure:
1 July 2014
Contact name:
Tatjana May (General Counsel and Company Secretary)
Tony Guthrie (Deputy Company Secretary)
Telephone number:
+44 1256 894 000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.


 
For further information please contact:

Investor Relations
    
Jeff Poulton
jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157

 
 
 


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

 
 
GRAPHIC 10 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP!#``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@+_Q`&B```!!0$!`0$! M`0```````````0(#!`4&!P@)"@L!``,!`0$!`0$!`0$````````!`@,$!08' M"`D*"Q```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T?`D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&A ML<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X M^?K_P``1"``\`+H#`1$``A$``Q$`_]H`#`,!``(1`Q$`/P#]_*`"@`H#;Y?J M'3VQ^&,T;:;6Z;6N&WD)T_SBC;3;MT"UO(S]2U;2]&M9+W5M0L]+LX@6>YOK MF&U@4`9.9)G1>!VSFMJ&'KXB:I8>C4K5&[*%*#E*[\HHY\3B\+@J;JXJO2PU M./VJLXP7XL\BO?VC?@MI\Q@E\>:3(ZMM)M!I5B*]VGPCQ# M.*E'+,1%-72DE!Z^3=[^7WGS-;CGABA/D_M*E)WM>FXN*[N[E'3Y%:[_`&E_ M@I96?VP^-[&=,D+!:6]Y/=D@9XMDMQ(,]BP4$\`YK2GP=Q#*:I_V=4I_WIM1 M@O5J[^Y&57C[ABA3]HL?&?:G2Y'4^2E4A'_R8PT_:D\`S`2VGA[XC7=CC>=2 MM?!\[V0C/27>;M)FC89(:.!R0#QG`/3+@O'4KQJ9EDU&I'>C/%8F-52_E(])\ M16"Z5%)CA)X M6I*M*,ITE2C*:J0CO.GRJ\HKKHFKJZ5SZ#!\193C,'+&PQ4*-&G.-.K[=QIR MHU)WY85%&4HQE*SLE)WUL]#8B\;>#II8X(?%/A^2::1(H8H]7L6DDED8+''& MBSEG=V(554$LQ``)K*>59E3BY3P&+A"*NY2H5(Q2ZMMQ21M#/,GG*,*>8X24 MI.T8QK1;;?1)/S.G'MQ^E<'X?@>JO+_+^KBT`'3\/ZT;?Y;!MY6^6YS=SXQ\ M)V-Q+:7?B70K2YMW,;7,H58 M2IRY6]^623L]=;'5A<9A<9!U,)7I5Z<9V/PQFC;;_(-O*WX7/./BM\1M M,^%?@S4?%6H)Y\D&VVTRP5@CZAJ5QE;:V4]53=F2=P,QPI(_85[&19/7SK,* M.!H^ZI/FJU$KJE237-*W?6R75L\#B3/DW;VE6UU'R7=_ MYGY*:YKGQ-^-^M7NIZC-=ZE!`7FD62?[!X6\.VNXD*TUP\>G6<40QF29VN92 M"Q+,:_H#"X+(>%\+3H0A256R5U%5,34J)*[LDZEV]>RT6A_,>.S#B'BK%3Q% M6I6C1);JS-QX?\,>(_&+;3_Q,--TRZL_# MBL/O?9+BYCAO-6"=%EACMK:0_,C3Q$%A\49?3FHXC%T,%_+3E4A*;6RYE&7[ MM]T]5LTGH*/"682I.6&PE?%2ZRY)TU%[MIM6FO-;GF>L^']=\.79L]?T74M# MNN66WU&RGLF8?],_-14D4?\`3-FP#SUY^@P>/P6-@I87$4JRMM"<9-7ZM)MK MOJCYW&Y=CL!/DQ>%JX=QVYZW&K^!KJ M:*UN+*Z2A+/REMK^[M?[6DDU3R8L*DLD M-Q;1&3:&F"ESGJ?B.!L56KY]@,'BFZE3!X;,(6J^]*DGRKV;(>`H87AW,,QP*6'I8W&9=42H^Y"=XR?.HQM&/6ZMNWL?"?@"*(>//!.(T7_ M`(J[PX1\H'_,7M/:OUO/:5..3XYQIP3CAY[12?PO5/H?BW#U:M_;.`3JU+>W MA=.3[KH?O"O"CMP/;M7\JO1OIJ_*Q_9L-(0_PQ\NB'4%!1Y?\"P;>5OU/Q@^ M-WA;Q!=?%OQ_<6WAO6KF";Q%=/#/!H]]-#*I2+#QS1V[)(O7#*Q!YY-?T=PG MC,)Y8X+VSFLI'C.D:4OF+'-'& MS(65EW@$$J1G(-?F7B15PM;.L/+"5*4Z?U&FG*C.,HJ7M*EU>#:3LUIYGZ]X M48?%8;(\7#%TJU*H\?)QC7C.$N5TXZI32=KGV-T_SBOS[\+?*US]1V^7RW"@ M`Z?YQ1MIM^%@"@`H#;RM\K7"@`H`*`"@`^G'I[4MO+\+`)T_#^M/RL'H>5?$ M_P"+_A+X5Z8]'\.6`$^K:I<,=L:10)N:*%I"%:XD`09(4.^$/ MMY/D&-SBK:A%4GV/Q`_:&NKCPWX4\^6;P7\)]%)75M6N/* MRIO[D@-:L8G3[5<2XECBD8!+8,B-^A9,J&"KSRKA6G#$X[EY<=FU;6G0CLW3 MY6N:TK\L8VC>_,]S\JSV>*QN'IYQQ=.>$P"ESX#**5XSJ3W7/&6D4X[R>KTL MGJ>':-\1;;Q=X_\``^D:[:Z;X6^%MEXCL&/A#3U^SZ#;6JR'RY]5*@/J=P\H MB-U>7I?)+;52/@?6XW(JN79/CL3AY5<9GO3IX#)88BG_LM)MV][ZWNS^J*#HNC3=!T_8\B5/V3CR9`!'M<.YO5R;-,-B( M594Z/M(QQ$;M1E2D[20-0T[@DEC^`1_ MQ7G@G_L;O#G_`*=[3TK];S]6R?'ZI?[//3:UXO\`S/Q/A^T&".=X MCQ(%;BOPC(^!6L)54U*:[QAI9=FVK]C^CN(/$;)\BE]5I7QF M)A%*2HM.G3E9>[)I[][:>;/'-._;HMS<*NJ_#RXMK4O\TMAKL=S,JD\8@GT^ MU1V`Y/[],GL*^BJ^%>*C&]#,*7-;X9P:UMKM+1=M#Y:AXQ4.=?6,OE&FG:]* M]TGZNUT?87PZ^)OA/XH:+_;7A6^,T<+B&^L;A/(U#3KAEW>3=VS'G0-)!9B..6\G2!&MBO#C-L%AZV M(GB,,X4*4ZLE'FNU3BY-+SLCQ\'XJY+B\30PM/"XN,\15ITHM\JBG.2BF_*[ M.Y^*_P"TAX&^%=R^CS&?7_$BH'?1=+:,&T##*_VA=OF&T9L@B$[YRIW>5C!/ MDY#P;FF>15:E%8;"]*]5-*?_`%[BK77G=+M<]?B7CW*.')2P\F\3BXZ2H46O MW;ZJIV=]TMNIA_`W]HN3XQ>(-9T1_"@\/C2].748[@:M]O,R/.L'DO&+&U\M M@6W[P[#^';_$=^)N#Y\-X>A7EB57]I+D<5#ELW=W6KTLCDX0XZ7$^+K8987Z MNJ<7.,E?9*]GKOZ6.V^)GQ\^'WPL;['K.H/?:VR;TT'256ZOU!&5:Z^98;)& MSE3?DG"F;9VU+"T?98?_H(K)QIZ;J-E>3]%;S/7X@XTR7AU.GB M*OM<2E_NU!Q=1?XM;1_%^1\Q77[=`%P?L/PZ=[56.&NO$*0W#KR!^[BTN:.- MNA/[R48./>OMH>%>(4;SS&FIVTY(>[%];^]K?LK>I^=U/&*DIOV.7OV:>G/= M2M\GN>H^`?VP/A]XJO+?2]>M;SP;?7,BQ02ZA)' MY@ACR1EQFO$S;P\SC+:I]9Q21RHDL+I)%(JR1R1L&1XV`971E)5E8$%6! M(8$$<5\"XN#<9)Q<6TXM6<7U371GZ;"<)QC.G)2A)*4)1::<7LTUI9IZ6)*1 M04`)^G_UZ7D"T\OPL?-WQF^.R>";FW\$>"+/_A)_B7K+);:?I%J//CTM[@$1 MW.H+'G]XH/FQ6C%-R`S3M'",O]AP]PR\="68YC+ZIE&'O.I5E[CK*.KA3;MH M]>::VV6NWP?%'%RRV<<5WR0IP]Y8=R=N:HE='J+-L\E]=S6J M_:6J>]3P[EK:,'>+DKVT5EZ[;'[1?PHG^*G@1K/21&/$>A7!U70UD(1+F01F M.ZT\N?\`5_;(3MC8_*)UB+?*"1EP?GT<@S55:J?U6O'V-=K>$6TU-);VUNNS MOT-^.N&I<0Y/*CAU;%8:7MJ$=N=I:T[]+]/^"?C_`*EIFH:)?76E:O8W.EZC M9.8KJPO87@N8)%)!#QN`<'^%ERCCYE9ABOZ0PV+PN-I0JX:I"I2J1YH\DD]& MKJ]KVOV^1_*N*P>+RZM*CB:53#5:%/BM\1?`QC7PQ MXMU;3[>-E9;&2?[9IXP>`;*\$T&S_8"!2.,8KR\PX9R7,T_K6"I-J_O4XJE. M[W?-%*5_.YZV6<59[D_+]3QU6FH[1G)SC;MRR=K>1]'^&?VU_'6G&*+Q/X?T M;Q!$N`\]HSZ/>,.,MB,3VF_J<+`B_3K7Q..\+\OJ)O`XJIA-'RQG>K&_FY-2 M^YH_0[KT?#?3B>@MK87%?C&)YOBOIPA5MHECL';YRJ=#\J;:XN+ M*YM[JTD>&ZM9XKBVEB.V6&XB=7ADB(Y$B2!60CD,`17]"UHTI4YQJI.ERRYD MUHXI-NZV/YBHRJ4ZT'0?+4YDH-:.\G96[7;/MGP+^QIK?B70[77_`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`+:\<:C_`<8,ATW3[9+""8C)1%N"\\\:,=N]GA M:0<[8^@_*:_BEB?;/ZOE\(T>;W5.K:3CW:4&D_1_B?LN&\'<.L.EB,PDJ_*F M^2G[L)6U6ZO9Z72LSY!^+_PDUKX0^)$T/5)X[^QO;UNS5MMTS['_8X^+%[JUM>_#/7;I[B?2+3 M^T?#=Q/(6E.EJZQW6F[F^9ULGDCD@RQ*0RF,?+&`/S/Q&X>IX*K#-\+35.E7 MGR8B,%RQ562;C-16D;I6EM=M/<_6O"KB>KBZ<\DQE1RJ4(.IAI2?O>SC;F@V M]7>]U?7MNS[PK\K/V@*`/FW]HCXWQ?"K0(],T4I<>-M?B>+2+0`2?V?"Q\I] M5N(][.+VZ>^]TF MDM7I\%QQQ9'A_"+"82TLSQ?N4(K_`)=J?NJ;2U3E?W/O[&5^SG\&)/"&GOX\ M\8A[_P"(7BI#?W=S?$S7.DVU[B7[('DRRWDV0][*N&&5ME(CC(._%O$*QM7^ MR\NM0RK!/V4(4O=C6E#3G:6G)>]EU?O/H^FR:ZWM]3=!CM7Q&S=M.RV]3]&]/\BO)=VD+%);FWB<`'8\T:,`>1 ME68$9[<I0*<`&*]M72Z0#``^?;TXKU,!FV;Y,[X3$8C#0O?V; MYE2;\X27+=^5F>'F>19#GB<<5AL-7J6M[6#A[6/SBW][3/F+Q-^Q%X5NC)+X M3\4:MHKMN*6FIQ1:I:HWE8^7OB!^S%\3_` M%I(]&M$:6>_\`#[S3/;P*"S37%A-'%=HD:C,SQI(B"22":&1989H7:*6"6,ADEB="KI(C`%64AE('2OM: ME*E7I.G.,94YQ:<9)--275;6U/@Z56KA:L:E*4J52G*Z:;BTXN_38^W/'?Q$ MO/B-^R=8WVJR^;K6C>-=!T/5)SP]S+:&9H+QQ_?N+:2,R-_'*LC#K@?DN59- M#)O$!4:$73P]?"8JM16RBG%<\8^2EMVO8_9\ZSRIG?AFZM=WQ&%Q^"HUI=]: MG*WYN._<^1/!MI#?>,/"EC.H:"[\2Z':S(1D-%<:G;1R*1QP58@U^EYS4>'R MS&5(W3IT*C5G;>+/R?(Z4:N:X&E):2Q$%:W:29^\R*%15``"JH`'```'``X% M?R>]WZM_.[/[5I)1ITXI648126VG*CXC_;AAC_X0OP=,4'FP^))TC<\,BS6+ M^8H/8/L3/KM%?I_ABT7QR>Q^0^,$8_V5E[:5XUZW*^JO"%[= MCXK^`Y*_&/X=;25_XJ:Q'''#%@P^C`D$=P:_3>,5_P`8YFFG_,+5\NA^0<#: M<49/;3_;*7E]H;\=>/C#\1,=O$EW^J14^#=.'^7!K]'Q-3V&'KU5I[.E4F MK:?#%L_+L)257$X:B]%4K4J;Z:3DD_S/W<\$^'+#PCX3\/\`AW38([:UTK2K M.V5(U"YD6%#-*^!\TDTS/)(YRSNS$Y-?R?F>+JXW'XK%59-SJUZDM7\,>9\L M5Y);']HY+@*.697@L'0C&,*6'IIV7+>3BFY.UM7>USX*_;EU*9M?\!:2&9;: M#2]7OVCY"-<3W-K;H^.A9(XI%&.0)6SPPK]8\*\/#V69U[>_[2E!=+*,6].N MO.[_`"/Q7QDQ$OK.58=.U.-*M)Q6EVVM7Z'R5\/?'^L_#+Q&GBCP_!ILVIQ6 MEQ9Q'5('G@ACN@HE=$CF@82E5"AM^-I(((-?HN=9-ALZPCP6*G5IT>92?LY* M#;332;[7UMU/RS(,\Q?#^-6-P5.G*M%6C[6+E&-UNDNMGN>]_P##9WQ;''V; MPCQ_U#+KO_W$*^/_`.(9Y`O^7^*^56*M^)]U_P`19XEV^K8/_P`%37Z'EOQ/ M^.'BWXLVFE6GBFVT*(:-%J5JN!KUI.O",)QJU(N-HMM-):*6K5^VA\UQ)Q?FG$U+#TL=AZ-/ZM M.4X3HTY1DW-6:;M\/5+NV^Y?_9NU*73/C5X%:!]HO-1ETV95(&Z"^M)XV4C( MXW;&(Y^[G!.*QXWH4\3P[CHMQO1HU:\5=?%1IRJ*UNON_B:\`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`\>._!/MXM\.?AG5[2OJ\^5LGQ__ M`%XG;_P%GQ?#W_(XP"_ZB(6Z6]Y'[OKPH[8`]L9%?RF]&[:6;\K79_:,-(1Z M6C'Y72/B7]N'_D1O"7_8SO\`^D$U?IOA?IFF-Z6P]/RM>K MY6O"!\3?`CCXQ?#KM_Q4]A[?Q-7ZAQC_`,DYFEO^@6K^1^/<#Z<49/T_VREY M?:$^.O\`R6'XB?\`8R7?_H$5'!VG#N7=+4(?*\43QKIQ)F*V_?3_`!G+\SU? MP=_R:9\3O^QZL?\`TGT*OFW[J+_T6M?R34TJ3Z>_.RVM[S/[:H_P:*VM3I^6T4?`G[9P*_6/"W'1IULPP+DE*JJ56G%Z?"I* M=O\`R4_%/&++YSIY;F$(OV=%5:5625E>37+Z-W^9\Q?L\WGA.V^*.BVGC/3] M,OM#UB*YTDC5X()[*WOKA5-E/()P8X@TR>3YK8"F51D`DU]SQM1S"625ZF7U M*M*KAVJO[ARC4E!-'KOV7[Y+V<&T[2 M=]M6OF?JL/A#\+2`1X`\)X/((T6PQSTY$/3W[U_/SSO-XOE_M'&)_P#7ZHOP MNC^FX\.9$TG'+<'RO6+5.+5GJFK:-69YE\2E_9Y^%%I877BOP;X:C;4IS!9V M5AX,7?1M6 M>MMC#^%WCS]GSQGXOLM+\!^"8K7Q#:0SZI;WP\)0Z<-/CM0-UP;T*#;L6D6. M,C#.\@4=375GF3<4Y3@I5LSQD_JTG[)P^M2GS^T33CR.UTTW?RNBDZ-6-11?KRV M.3,,-]=P&-P?-R_6\)B<-S?R^WHSIS/YRRRAG/`?$-3$U\!6JX252 M<92A%OVE&5TG%KR?-?YGW=H?[2_PMUN%&@O-=M;@@;K&X\-:T;I'/5-EM9SJ MV"<;D8JW!!P:_*,5PIF^#E-2ITI0BW:I"M!0:Z25VG%/?5(_:<'QMDN+A%PE M6IS:3=*=*2E"3WC=:?,[RQ\?2:T!_P`(_P"$O%%VAY6ZU&P.@6&T\[A/JC12 M2#OMCMV8],9->5+`1H*3KXK#TVGI3C)U)OO905EOU:_`]FGF[VZW.=^+GPFM/C!X+72-5$&D^(+3-[H^HQ9N4TS4"N'B+%8WFL M[E%6*Z4*I(Q(@WQI7IS!5Z'-/#RM3KT_AYZ;=VTKZ36O+T=VGO=>3 MQ1PU1XERMX:LHTL533G0J+:%2SM%O?E?EU^9^2?CKX:>-/AOJ,NG>*M$N[() M(5@U&.)Y]*O4R=LEK?1H86#KAA'(R2KDJR94U_0V4<0Y9G%&$\)B8<_*G*E) MJ-2F^L91=K=5YG\P9SPSFV0UITL7A:L8QDU"K&+<)QZ2BXWW6J9EZ)XU\7>& MHQ%X>\4Z[HL*G<(=/U.ZMH5/JL:2>6O?[J@5UXK)\JQDG+$X+"UI/5RG"#;3 M\SEPN=YS@*:I83'8O#0CM"$IQ2^7];E?6O%?B3Q'M_M_Q#J^L;3N5-2U"YNH MU8=&$^W//%/"Y9EN!?-A<)AL.TK7A&$6EZD8O-F_"GX$^-?BEJ-K]DT^YTGPUYJ'4?$5]`\%LEMN!D&GI*J-?W3)D1+ M"/)#8:20*#7@\0\7Y9DF'J1A6A7QEI1IX>#NU*SLY-:1C?=O\3Z+AG@C-<_Q M%)^PEA\%&2=3$5(N,>6]VEUYGVMKL?:'[4/AC2O!G[.^E^&-$@%OINC^(?#% MI;H!AVV/=>9/*0/FFN)2\TS]7DD8]Z_+^",=5QW&/UW$S7M*U#%SDV[*-X+E MBKVT2T7IW/U[Q#RRCE?`<7@#MP/Y5_*ST;MT?33=G]FPTA'I:,?+='Q-^W!_P`B-X2[ M?\5._P"'^@2^E?IGAC*,,TQG,U%>PIK5J/VY=['Y'XO1D\IP"A&3?UBK\*;M M[L.B1\3?`C_DL?PYP/\`F9[#L?5J_3N+ZE/_`%FFXGQU&/C#\1.",>)+OL1U2(^G>EP?4IKA_+HN M<(VH0TYDMX+=7%QG1J_ZQYBU3J->VG:T)?S2VLK'J_@[_DTSXG8!_P"1ZL>Q M'_+OH5?-YO.'^O\`E+4H\L62?\` M`?2WY'S'H@QK>B#!_P"0SI78_P#00MZ_0,PJ4_J.,2J4_P#=JMO?C?6#\^I^ M:Y92J?VC@+4JBMB\.W[DE;]Y'^[H?OI;\00]OW4?M_`M?R94TJ5+=)R\MY,_ MM>A_!HK:U*GY?91R?C[P3I'Q!\*:MX3UN,FSU*`JDJ`>=9W2'?:WL&>DUO,% MD7D;@"A.&-=N59EB,HQU#'89\M2C+57Y5*#^.#MTFM+]'J>=G>48?.LNQ&7X MF*Y*L?==E[E1)\DUZ-^6A^.?Q*^$7C/X5ZK-9:_IL\FG"9O[.\06D4CZ7>PA MLQ2"=%(M;@KC?;SE)$DSLW``G^CLBXERW/,/%TJL(5N3EK8>HU&<7]K1V]V[ MT:T:/Y4XAX3S7AO%RC5H5704KT,133<6D[IIK^K[E_1OC[\7]`T]-+TSQUJB M6448BBCNEM+^2"(#"I!<7L$\\2H.%V2#;CBHQ'"'#F*JNM/`T%)2YI>SM%2; MWYDFE+YFF%XUXFP-%8>ECL3R17+!2E.\%VB<7+<>,OB/X@C,LFM^+_$=^RPQ M[C/J%XP+?*BXW+;VZ$_],H8QRQ45Z45E&08-\BP^`P])-OEY8)_<]WL>5)YU MQ%C8J7UG&XFI*T>;FDU?LVM%J?J3^S;\$'^%.@W&IZZL3^,-?2(Z@(RKII5D MGSPZ7#*O#LKL9;N13LDFP%^6,$_@_&7$[S[&*EA[QP.&;5);>TEM[1KLDVH= M;-OJ?T?P#P>N&L$ZV)BO[0Q$5[31?N8.S=-/HW]I+:UNY]-5\4?H84`,>*-U M*O&CKW5U#+^*L"*<92@_=E*+_NMQM]S1$J5.2M.G"26RG&,K?^!)D4=I:0G, M-K;Q'UCACC/YJHJG5J-6=2HUV.'H1?=4J<7]ZBB<`#@#'L. M*@U22T2Y5V6GX=!:!E2\L+'4('M;^SMKRVD!5[>[@BN(6!ZAHY59#D>HK2E5 MJ49*=&I.E..TH3E!KT<6C&MAZ&(@Z=>C3JP:MRU(1DK/M=:?*QYE??`KX0:A M,9[KX>^&VE))+169M(L[Q2:K9C7:[0]G17W484S7"\(\.8*2EALK MI0<=N>KB*OX5JU1?>CTB***!%BAC2".,;4CB18T4=@J(`J@>@&*\9RDVW)MO MO)MO\3Z"%.G2BHTH0I1CM&$5"*]%%)(@O+"RU"'[-?V=M>V^Y7\B[@BN(=ZY MVOY:NG5J4)<]&I.C-)KFIR<)6>ZO%IV?4FM0HUX>SKTH5* M=T^2<4XW6SL]+]F9L?A?PW#(DL7A_1HI(G5XY$TRR1XW4AE=&6$,C*P#*RD$ M$`@YK:6.QK3C+%8AQV<76J-6\US6.:&69=3:E3P6&@XZIQHP33[IVT^1NXQ[ M5R[>5OE:YW)6VT*5[ING:BB1:A86=]'&V]([RVAN$1R,;D69'56P2-P`..,U MI2K5<.VZ-6I1;W=.R:T*4'AOP]:31 MW%KH6D6T\+!XIH=.M(I8W'1XY$A5D8=F4@CUK6>,Q6X"C.,Z6#P].<7>,HTH1E%KJFEHPG\-^'KF:2>YT+2)YY&+R33:=: M22R.>K/(\)=V/+Q-FK- M.O4M9[IKF,XY7ET&I1P.&BU9IJC!--;-::&Z`%Z#';'2N3;Y?J=R]VR6BCLM MK"]/;'Z9H#;RM^%RK=V5G?026M[:V]W;2#;);W4,<\+J>H:.561A[$5=.I4H M24Z4YTI1^&4).$E\XM,RK8>A7@Z=:E3JP:LXU(1DM?)K3U6IYQ=?!+X27DYN M;GX>^%GF)W%_[+ACY)SG;&$3K_LXKV*?$>>48>SIYCB(QM:SY)/_`,"E!R_$ M^?J<'\-U)^TGE5)SWNJN)@M=_=A7C'\#L-"\)>%_#$9B\/>'](T5",,-.L+> MU8@=F>*-7;_@3&O/Q./QF+=\3B:U;6]IS?*O2.D5\D>K@\JR[+U;!X.CA_., 26Y?^!SA_78*`/_9 ` end